Summary Preoperative staging of gastric cancer is difficult. Several molecular markers associated with initiation and progression of cancer seem promising for obtaining preoperative prognostic information. To investigate whether these markers are indicative especially for the presence of lymph node metastases in patients with gastric cancer, we have examined primary tumour specimens from 105 patients with primary adenocarcinoma of the stomach entered in a surgical trial. In this trial, lymph node status was determined by strictly quality-controlled lymph node dissection and examination. The selected markers were growth regulators (p53, Rb and myc), metastasis-suppressor gene product (nm23), adhesion molecules (Ep-CAM, E-cadherin, CD44v5 and CD44v6) and urokinase-type plasminogen activator (u-PA). Also, the amount of eosinophilic and lymphocytic infiltrates available post-operatively was analysed with respect to its prognostic value for lymph node status. Moreover, the association of these parameters with survival and disease-free period (DFP) was evaluated. Of all molecular markers investigated, only Rb expression had a significant association with the presence of lymph node metastasis in both univariate and multivariate analysis. For curative resectability, a significant association was found with Rb and E-cadherin expression, while in multivariate analysis Rb and myc were selected as the combination with additional independent prognostic value, and E-cadherin had no additional independent value. For overall survival in univariate analysis, the amount of both eosinophilic and lymphocytic infiltrates and Rb and myc expression were of significant prognostic value. Only the amount of lymphocytic infiltrate had a prognostic significance for DFP. In stepwise multivariate analysis, TNM stage (I+II) and marked lymphocytic infiltrate were associated with better overall survival and longer DFP. We conclude that, if these results are confirmed in a larger series of patients, molecular markers can provide useful prognostic information.
Despite declining incidence, gastric cancer remains a major clinical management problem with poor prognosis: overall 5 year survival rates vary between 5% and 11%. Only a curative resection (complete tumour removal) offers hope of a cure, but the majority of the patients are diagnosed at an advanced disease stage (Allum et al., 1989) . At diagnosis, the first decision to be made is whether or not to attempt a curative resection. This decision is based on stage of disease, which is assessed by radiograph of the stomach, chest and ultrasound of the liver or computerised tomography (CT) scan of the abdomen. Palliative resections offer no survival advantage and are associated with higher operative mortality rates compared with curative resections (Allum et al., 1989; Akoh et al., 1991; Wanebo et al., 1993) . Laparoscopy and cytological examination of abdominal washings increase the accuracy of preoperative staging, but are not used routinely (Bonenkamp et al., 1996) . Therefore, there is a need for additional, reliable prognostic factors by which tumour aggressiveness can be determined, and the presence of lymph node metastasis and resectability for cure can be predicted, preferably by analysis of biopsy specimens. This would allow better selection of patients suitable for surgery.
A variety of genetic changes are implicated in the process of carcinogenesis and the development of metastasis. These changes are associated with altered expression of proteins, which were reported to be of prognostic significance in different types of malignancies, including gastric cancer. However, not all of these tumour markers have been analysed in the same specimens and it is not known whether some of these markers are superior to others or whether a combination of several markers has a better predictive value with respect to the presence of lymph node metastasis. As prognostic tumour markers, proteins known to be associated with different steps of carcinogenesis (growth promotion, loss of adhesion, invasion of gastric wall and vessels and distant metastasis) were analysed.
Our first aim was to study the association between the absence or presence of expression of these tumour markers and lymph node status. In addition, the results were also related to powerful clinicopathological prognostic factors, such as infiltration depth (T stage), TNM stage and curative resectability. Staging and curative resectability can be assessed reliably pre-and post-operatively only and are, therefore, of no use for patient selection for surgery.
A second aim was to study the prognostic value of these markers in addition to parameters only determinable postoperatively (eosinophilic and lymphocytic infiltrates) for survival and disease-free period (DFP).
Patients and methods Patients
Between August 1989 and July 1993 a randomised, controlled multicentre trial was conducted in The Netherlands (Dutch Gastric Cancer Trial, DGCT) to compare the therapeutic efficacy of extended lymph node dissection (NI and N2 levels, so-called D2) with that of limited lymph node dissection (N1 level, so-called D1) in gastric cancer patients operated on with curative intent. In this trial 1078 patients were entered, 996 of whom met the eligibility criteria. Strict quality control measures were taken to obtain optimum lymph node retrieval and, thus, post-operative staging. In patients undergoing a curative resection, the presence of nodal involvement was assessed histologically and the actual number and location of Sections (4 ,um thick) were cut, mounted on precoated slides and kept at 37°C overnight. The sections were dewaxed in xylol for 20 min and endogenous peroxidase activity was blocked by methanol/hydrogen peroxide.
The antibodies used were p53 (mAb NCL-p53-DO7, Novocastra Laboratories), Rb (NCL-RB, retinoblastoma gene protein clone 1F8, Novocastra Laboratories), myc (NCL-cMYC, human c-myc protein clone 9E1 1, Novocastra Laboratories), nm23 (CRB-nm23 Hl, H2, CRB), Ep-CAM (323/A3), Centocor, Malvern, PA, USA), E-cadherin (anti-Ecadherin clone HECD-1, Zymed Laboratories), CD44v5 and v6 (monoclonal antibodies VFF8 and VFF18 against CD44 variants containing splice variants vS and v6 respectively, Bender, Vienna, Austria) and urokinase-type plasminogen activator (u-PA), a proteolytic factor (human urokinase monoclonal antibody against B-chain, American Diagnostica).
For p53, Rb, E-cadherin and CD44 splice variants, the sections were first boiled in citrate buffer (pH 6.0) for 25 min. For myc and Ep-CAM the sections were pretreated with trypsin (0.1% trypsin with 0.1% calcium chloride) pH 7.4 at 37°C for 20 min. Normal goat serum was applied to reduce non-specific antibody binding. The primary antibody was then applied and incubated overnight in its optimum dilutions in phosphate-buffered saline (PBS)/1% bovine serum albumin (BSA). The optimum dilutions for primary antibodies mentioned are summarised in Table I. For E-cadherin, a double-step detection system was used: biotinylated rabbit anti-mouse IgG was followed by the streptavidin-biotin complex (each incubation 45 min). For the remaining monoclonal antibodies (Rb, myc, Ep-CAM and p53), a secondary antibody rabbit anti-mouse (RAM) was followed by a tertiary antibody swine anti-rabbit (SWAR). Nm23 (polyclonal antibody) was preincubated with normal goat serum for 10 min before applying SWAR. In negative controls the primary antibody was replaced by PBS. The sections were stained with 3-amino-9-ethylcarbazole (AEC) in dimethylformamide with hydrogen peroxide and counterstained with Mayer's haematoxylin.
Assessment and statistical analysis of marker expression
Expression of all proteins, except u-PA, was scored as present () 50% of the tumour cells positive) or absent (< 50% of the tumour cell positive). (Iwasaki et al., 1986; Yu et al., 1995) and human colonic cancer (Pretlow et al., 1983) to be associated with prolonged survival. The same association was found for marked lymphocytic infiltration in gastric and rectal cancer (Yu et al., 1995; Jass, 1986) . The study of Yu et al. (1995) shows clearly that a standardised, quantitative analysis is needed, since there was high interobserver variation. Moreover, because these parameters can only be assessed in resected tumour specimens, they are not useful for preoperative staging or the prediction of resectability. In the present study, only the amount of eosinophilic infiltration was significantly associated with metastatic/unresectable tumours (Table II) and actual surgical procedures (Table III) .
We have compared the expression of several proteins, associated with different steps of carcinogenesis and development of metastasis, with lymph node status, T stage, TNM stage and with curative resectability. In univariate analysis, a clear association was found between Rb expression and nodal involvement. Also, in multivariate step-wise logistic regression analysis, positive Rb expression was the only significant prognostic factor for nodal involvement out of all the molecular markers (RR 3.66). Alternatively, the risk of the operation becoming palliative was predicted with an overall accuracy of 77.0% by the combination of Rb and myc. The Rb gene is a tumour-suppressor gene, which is frequently mutated in a wide range of human cancer types (Bartek et al., 1992; Harbour et al., 1988; Cryns et al., 1994) . Although until now nothing has been known about altered Rb expression in gastric cancer, decreased expression is reported to be associated with invasion in bladder carcinoma (Cordon-Cardo et al., 1992), whereas it had no prognostic value in breast carcinoma (Pietilainen et al., 1995) . Since Rb is a tumour-suppressor gene, mutations leading to decrease or loss of Rb expression are expected to be associated with an unfavourable prognosis. However, not all Rb mutations result in the loss of immunohistochemically detectable expression. Instead, mutations that do not abolish the production of the Rb protein may lead to the production of a not functional, nuclear Rb protein (Mittnacht et al., 1991) . It has been demonstrated (Xu et al., Rb myc nm23 Ep-CAM E-Cad VFF8 VFF18 u-PA Total Lymphocytic Eosinophilic characteristics Ti   17  38  53  41  24  53  53  18  85  15  16  56  44  44  56  T2  51  41  41  49  51  59  66  28  90  45  44  70  30  66  34  T3  17  35  65  47  71  77  53  33  94  21  17  82  18  71  29   T4  16  27  75  6  44  38  100  25  88  71  3  100  0  100  0   TNM stagec   I  38  34  40  45  45  50  61  28  87  33  34  59  41  50  50  II  18  47  50  44  50  72  53  25  100  40  16  94  6  69  31   III  16  19  50  56  56  75  63  15  92  42  16  62  38  69  31  IV  28  52  71  29  57  50  79  33  83  46  14  76  14  86  14  Operation  Curative  69  34  41  48  51  62  59  24  89  36  64  67  33  58  42  Palliative  36  48  78  28  47  50  81  37  90  45  17  88  12  88  12 aResection specimens were available for 81 cases. Missing cases b(n 4), C(n =5) are left out of the analysis. (%), row percentages; bold, statistically significant difference (P <0.05); Lymphocytic and eosinophilic infiltration 1, no or few; 2, moderate; 3, marked. (Heider et al., 1993) , for unknown reasons, whereas the findings with u-PA were similar to earlier reports (Nekarda et al., 1994) . In univariate analysis, we found that moderate and marked eosinophilic infiltration, marked lymphocytic infiltration, Rb and myc expression had a prognostic value for overall survival. Moderate eosinophilic infiltration was just as favourable as marked eosinophilic infiltration, whereas only marked lymphocytic infiltration had a strong association with longer survival. Since there is a correlation between the presence of lymphocytic and eosinophilic infiltrates, these two parameters had no additional value to each other. In multivariate step-wise Cox's regression analysis for both overall survival and DFP, the best prognostic information was provided by TNM stage and lymphocytic infiltrate (Table V) . TNM stage is the most important prognostic factor for survival and also for DFP. The presence of marked lymphocytic infiltrate was the only parameter with an additional prognostic value to the TNM stage, while none of the markers had an additional prognostic value.
In conclusion, a prognostic significance of the tumour biological marker Rb was demonstrated in a large series of gastric cancer patients. Adding also post-operatively obtained information, lymphocytic and eosinophilic infiltrates proved to be important prognostic markers for surgical procedure in patients with gastric cancer. The presence and amount of these infiltrates should, therefore, be added to other postoperatively determinable prognostic factors in gastric cancer. To establish reproducibility and the place of tumour markers (n) 
